Literature DB >> 7482745

Enzymatic removal of alpha-galactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies.

J A LaVecchio1, A D Dunne, A S Edge.   

Abstract

Xenotransplantation of tissues between discordant species such as pig into human is not yet feasible due to the problem of hyperacute rejection. This rapid response to xenogeneic tissue is mediated by natural antibodies that react with antigens on the xenograft. A number of xenoantigens consist of carbohydrate residues, and a terminal galactose in alpha linkage has been shown to be involved in hyperacute rejection of pig-to-human xenografts. We show that alpha-linked galactose on porcine endothelial cells is a major epitope recognized by IgG and IgM antibodies present in monkey and human sera. Endothelial cells that had been treated with alpha-galactosidase did not react with fluorescein-labeled Griffonia simplicifolia I B4 (GS-IB4), a lectin that detects the alpha-galactosyl epitope on intact cells. The reactivity of both human and cynomolgus monkey serum with endothelial cells was decreased by 59% to 90% after treatment with coffee bean alpha-galactosidase. Using a colorimetric assay for cell viability, we show that natural antibodies present in the sera of cynomolgus monkey and humans are cytotoxic to porcine endothelial cells in the presence of exogenously added complement. When the terminal alpha-galactosy residues were removed by enzymatic digestion, the cytotoxic effect of natural antibodies on porcine endothelial cells was diminished by > 80%. Evaluation of the time course of reappearance of the alpha-galactosyl epitope at the cell surface revealed that 48 hr after alpha-galactosidase treatment, binding of GS-IB4 was diminished by 60%. These results suggest that glycosidase treatment of cells to be transplanted could prevent hyperacute rejection mediated by natural antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7482745

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Immune response to biologic scaffold materials.

Authors:  Stephen F Badylak; Thomas W Gilbert
Journal:  Semin Immunol       Date:  2008-02-20       Impact factor: 11.130

Review 2.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

Review 3.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

4.  Combined transgenic expression of alpha-galactosidase and alpha1,2-fucosyltransferase leads to optimal reduction in the major xenoepitope Galalpha(1,3)Gal.

Authors:  N Osman; I F McKenzie; K Ostenried; Y A Ioannou; R J Desnick; M S Sandrin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Immunological and functional features of decellularized xenogeneic heart valves after transplantation into GGTA1-KO pigs.

Authors:  Robert Ramm; Tobias Goecke; Peter Köhler; Igor Tudorache; Serghei Cebotari; Anatol Ciubotaru; Samir Sarikouch; Klaus Höffler; Friederike Bothe; Björn Petersen; Axel Haverich; Heiner Niemann; Andres Hilfiker
Journal:  Regen Biomater       Date:  2021-08-03

6.  Histologic Characteristics and Mechanical Properties of Bovine Pericardium Treated with Decellularization and α-Galactosidase: A Comparative Study.

Authors:  Byoung-Ju Min; Yong Jin Kim; Jae-Woong Choi; Sun Young Choi; Soo Hwan Kim; Hong-Gook Lim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-12-07

7.  Removal of alpha-Gal epitopes from porcine aortic valve and pericardium using recombinant human alpha galactosidase A.

Authors:  Seongsik Park; Woong-Han Kim; Sun-Young Choi; Yong-Jin Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

8.  Transgenic pigs designed to express human α-galactosidase to avoid humoral xenograft rejection.

Authors:  J Zeyland; B Gawrońska; W Juzwa; J Jura; A Nowak; R Słomski; Z Smorąg; M Szalata; A Woźniak; D Lipiński
Journal:  J Appl Genet       Date:  2013-06-19       Impact factor: 3.240

Review 9.  Residual Bioprosthetic Valve Immunogenicity: Forgotten, Not Lost.

Authors:  Paul Human; Deon Bezuidenhout; Elena Aikawa; Peter Zilla
Journal:  Front Cardiovasc Med       Date:  2022-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.